Letter to the EditorFree Access
Future perspective on pharmacogenomics of severe hypoglycemia associated with sulfonylureas: reply from the authors
Published Online:19 Dec 2011https://doi.org/10.2217/pgs.11.163
Abstract
A letter in response to: Holstein JD, Kovacs P, Patzer O, Stumvoll M, Holstein A. The Ser1369Ala variant of ABCC8 and the risk for severe sulfonylurea-induced hypoglycemia in German patients with Type 2 diabetes. Pharmacogenomics 13(1), 5–7 (2012).
References
- 1 Holstein JD, Kovacs P, Patzer O, Stumvoll M, Holstein A. The Ser1369Ala variant of ABCC8 and the risk for severe sulfonylurea-induced hypoglycemia in German patients with Type 2 diabetes. Pharmacogenomics13(1),5–7 (2012).
- 2 Sato R, Watanabe H, Genma R et al.ABCC8 polymorphism (Ser1369Ala): influence on severe hypoglycemia due to sulfonylureas. Pharmacogenomics11(12),1743–1750 (2010).
- 3 Chia CW, Egan JM. Incretin-based therapies in Type 2 diabetes mellitus. J. Clin. Endocrinol. Metab.93(10),3703–3716 (2008).
- 4 Seino S, Zhang CL, Shibasaki T. Sulfonylurea action re-revisited. J. Diabetes Invest.1(1–2),37–39 (2010).
- 5 Zhang CL, Katoh M, Shibasaki T et al. The cAMP sensor Epac2 is a direct target of antidiabetic sulfonylurea drugs. Science325(5940),607–610 (2009).
- 6 Travers ME, McCarthy MI. Type 2 diabetes and obesity: genomics and the clinic. Hum. Genet.130(1),41–58 (2011).
- 101 The Ministry of Health, Labour, and Welfare in Japan. Pharmaceuticals and Medical devices safety information. No. 275, December 2010 (In Japanese). www1.mhlw.go.jp/kinkyu/iyaku_j/iyaku_j/anzenseijyouhou/275.pdf
